China’s NMPA approves Zydus-licensed anaemia drug Desidustat
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
One task, one interaction, one pair, experts advocate
The conflict is also triggering a widening public health emergency
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Marks significant milestone for breakthrough biologic to treat rare blood cancers
Subscribe To Our Newsletter & Stay Updated